A perspective calls for broader ALS models beyond protein-focused mouse studies
Original source
Protein-First, but Not Protein-Only: Rethinking Neurodegenerative Diseases Through Transgenic Mouse Models. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Population inferred from the title and abstract by Compass.
A perspective article argues that protein-centered research remains useful for amyotrophic lateral sclerosis (ALS), but should be combined with models that capture other disease processes. It recommends using portfolios of genetically engineered mice alongside human cell models, postmortem tissue, omics and biomarker validation.
Why this matters
This mainly affects researchers planning preclinical ALS studies. The authors say mouse models can help investigate proteins such as TDP-43, SOD1, FUS and C9ORF72-associated proteins, but may not fully represent sporadic, aging-related disease. The perspective does not change treatment for people with ALS.
Limitations and context
This is a perspective article, not a report of a new clinical study or treatment. Its recommendations are based on discussion of existing experimental models. The article identifies limitations including artificial overexpression, emphasis on familial mutations, species differences and incomplete modelling of aging-related sporadic disease.